Lennart Tonneijck

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Erik J.M. van Bommel, Marcel H.A. Muskiet, Michaël J.B. van Baar et al. · Kidney International · 2019 · 331 citations · Full text

Metabolic Syndrome, Diabetes Management, Renal Function +13

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial

Marcel H.A. Muskiet, Lennart Tonneijck, Yao‐Kuang Huang et al. · The Lancet Diabetes & Endocrinology · 2018 · 248 citations

Diabetes Management, Cardiovascular Disease, Medicine +7

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Mark M. Smits, Lennart Tonneijck, Marcel H.A. Muskiet et al. · Diabetologia · 2016 · 136 citations · Full text

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Lennart Tonneijck, Mark M. Smits, Marcel H.A. Muskiet et al. · Diabetologia · 2016 · 124 citations · Full text

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Lennart Tonneijck, Mark M. Smits, Marcel H.A. Muskiet et al. · Diabetes Care · 2016 · 112 citations